Insulin Syringes Market

Insulin Syringes Market Latest Trends

The Insulin Syringes Market is moving toward products designed to improve injection comfort, dosing visibility, manufacturing consistency, and medication utilization. The 0.5 mL category held 44.22% share in the latest capacity assessment, demonstrating strong demand for a format suited to routine insulin administration. Fine needles and carefully engineered bevels are increasingly used to improve skin penetration while maintaining dependable medication flow.

Low-dead-space engineering is gaining attention because residual medication inside the syringe can contribute to avoidable wastage. Manufacturers are also refining barrel transparency, graduation contrast, plunger retention, siliconization, and fixed-needle construction. These improvements are particularly relevant for users who administer insulin independently and must accurately identify the prescribed dose.

Safety engineering represents another development direction. Passive needle-retraction technology and other protective mechanisms can reduce occupational exposure after injections while maintaining familiar clinical technique. Healthcare facilities increasingly evaluate such characteristics when selecting injection devices for professional settings.

Concentration-specific syringe design is also gaining importance as concentrated insulin formulations are used for selected patients. Clearly differentiated scales can reduce reliance on manual dose conversion and support safer administration.

Manufacturing localization represents a further trend. Healthcare systems are placing increased emphasis on reliable domestic or regional supply chains following disruptions and quality concerns affecting imported devices. Producers are responding through automation, additional production lines, inspection technology, and manufacturing-network diversification.

Insulin Syringes Market Dynamics

Insulin Syringes Market dynamics are shaped by persistent diabetes-treatment requirements, recurring consumption of disposable products, alternative delivery technologies, regulatory scrutiny, and differences in healthcare access. Type 2 diabetes accounted for 91.05% of syringe demand by diabetes classification in a recent market assessment. This patient population creates a substantial addressable base when insulin becomes part of prescribed disease management.

Syringes retain practical advantages because they require limited supporting infrastructure and allow users to visually verify medication before administration. Institutional purchasers emphasize consistent specifications, sterile supply, procurement reliability, and clinical safety. Home-care users focus on manageable injection technique, dose readability, needle comfort, and convenient availability. Competitive pressure is nevertheless increasing as insulin pens, pumps, and connected delivery devices gain adoption. Manufacturers must therefore balance affordability with improvements in quality, safety, usability, manufacturing resilience, and product differentiation.

Drivers of Market Growth

Expanding diabetes treatment requirements are sustaining recurring demand for insulin administration products.

The principal demand driver is the continuing need to administer insulin to patients whose treatment requires injectable therapy. Worldwide diabetes prevalence has reached 830 million people, establishing a substantial clinical population requiring long-term disease management. Insulin remains essential for people with type 1 diabetes and is prescribed to selected people with type 2 diabetes when their treatment pathway requires it.

Syringes remain especially practical where insulin is supplied in vials. Their established clinical familiarity enables healthcare workers, caregivers, and trained patients to use them without electronic infrastructure. The ability to visually draw a prescribed quantity also supports individualized administration.

Single-use consumption creates recurring product requirements throughout treatment. Hospitals require dependable supplies for institutional administration, while pharmacies support patients managing injections at home. Expansion of diabetes diagnosis and access to insulin can consequently translate into additional demand for compatible administration products. This connection between chronic treatment and repeated device consumption supports continued market activity.

Market Restraints

Increasing adoption of insulin pens and automated delivery systems is reducing dependence on conventional syringes.

The most significant structural restraint is the transition toward alternative insulin-delivery formats. The European Region has the world's highest burden of type 1 diabetes, creating an important environment for adoption of advanced delivery technologies. Insulin pens can simplify dose preparation, improve portability, and eliminate the requirement to manually draw medication from a vial.

Pump systems create additional substitution pressure by delivering insulin through programmable infusion rather than repeated syringe injections. Connected pens and automated insulin-delivery systems can also provide digital records that conventional syringes cannot generate.

These technologies are particularly competitive where reimbursement makes advanced devices accessible to patients. Younger users and digitally engaged patient groups may also favor systems integrated with glucose-monitoring technologies.

Traditional syringe manufacturers must therefore preserve advantages in affordability, broad availability, simple operation, and flexible dosing. Suppliers that depend heavily on conventional products face increasing pressure to diversify into complementary injection technologies as diabetes-management practices continue evolving.

Market Opportunities

Improving diabetes treatment access in underserved populations creates substantial opportunities for economical injection devices.

Access to diabetes medication remains uneven across global healthcare systems. Over half of people living with diabetes were not receiving treatment in the latest worldwide assessment, demonstrating a major gap between disease prevalence and therapeutic coverage. Expansion of primary healthcare, diagnosis programs, insulin availability, and pharmacy infrastructure can create additional demand for straightforward administration products.

Local production offers manufacturers an opportunity to serve these populations while reducing dependence on long-distance supply chains. Automated assembly can support standardized output, while regional distribution networks can improve availability outside major metropolitan areas.

Manufacturers can also develop packaging suited to home treatment, incorporating clearer instructions and disposal guidance. Partnerships with hospitals, pharmacies, diabetes organizations, distributors, and public-health procurement programs can strengthen product reach.

The opportunity is particularly relevant in markets where sophisticated electronic devices remain inaccessible to large patient populations. Affordable syringes can maintain an important position when healthcare priorities emphasize dependable access to essential diabetes treatment rather than advanced digital functionality.

Market Challenges

Maintaining consistent quality across high-volume production remains a critical operational challenge.

Insulin syringes require precise manufacturing despite their relatively simple mechanical structure. Terumo's insulin syringe design incorporates a 3-bevel needle configuration intended to support comfortable penetration. Manufacturing must consistently control needle geometry, barrel dimensions, scale printing, plunger movement, component assembly, sterility, and packaging integrity.

Dose accuracy is particularly important because insulin is administered according to carefully prescribed quantities. Poorly printed markings, component defects, or inconsistent plunger behavior can affect usability and increase clinical risk.

Manufacturers must also manage sterilization operations, medical-grade raw materials, transportation conditions, supplier qualification, and regulatory documentation. Institutional purchasing can simultaneously create significant price pressure for standardized disposable devices.

Used-product disposal presents another challenge because needles require suitable sharps-management procedures. Suppliers therefore operate within a demanding environment in which affordability, precision, patient safety, regulatory compliance, and large-scale production must be maintained simultaneously.

Insulin Syringes SWOT Analysis

Strengths

• Established clinical familiarity: Insulin syringes have long-standing acceptance among healthcare professionals, caregivers, and patients using vial-based insulin.

• Flexible dose preparation: Users can draw the prescribed quantity rather than depending exclusively on predetermined device configurations.

• Simple operating principle: Conventional syringes require no electronic interface, charging system, connectivity, or software support.

• Strong standardized segment: U-100 products represented 69.65% of concentration-based market share, providing manufacturers with a broadly established product specification.

Weaknesses

• Manual dose preparation: Patients must correctly draw insulin and interpret graduation markings before injection.

• Limited connectivity: Traditional syringes cannot automatically store or transfer administration information to digital diabetes-management platforms.

• Disposable waste: Each device creates sharps and plastic waste requiring responsible handling after use.

• Device substitution: Advanced insulin-delivery products provide functionality unavailable in a conventional syringe.

Opportunities

• Home-care expansion: Increasing emphasis on chronic-disease self-management creates demand for convenient patient-oriented injection supplies.

• Safety engineering: Passive protection systems can help suppliers differentiate products intended for professional healthcare environments.

• Localized manufacturing: Regional production can reduce exposure to import disruptions and strengthen procurement resilience.

• Institutional channel potential: Hospitals and clinics accounted for 47.25% market share, supporting opportunities for suppliers capable of meeting large procurement requirements.

Threats

• Insulin pen penetration: Pen systems provide convenient dose selection and portable administration.

• Pump adoption: Infusion technologies can reduce repeated use of disposable syringes among eligible patients.

• Procurement pressure: Standardized products face aggressive competition in hospital tenders and distributor negotiations.

• Regulatory scrutiny: Product-quality concerns can trigger supplier reviews, import restrictions, recalls, or changes in purchasing policy.

Insulin Syringes Segmentation Analysis

Insulin Syringes Market segmentation reflects differences in prescribed dose, insulin formulation, diabetes classification, and treatment environment. The market is divided into volume capacity, insulin concentration, diabetes type, and end-user categories. Each dimension influences purchasing decisions because patients and healthcare providers require products suited to specific treatment protocols.

Capacity determines the amount of insulin that can be drawn and the spacing available for dose graduations. Concentration determines the scale required for accurate administration. Diabetes classification influences treatment duration and insulin dependency, while end-user segmentation identifies whether administration occurs under professional supervision or through patient self-care. Together, these categories help manufacturers plan product portfolios, packaging formats, distribution strategies, and manufacturing capacity. Segment-specific design also enables suppliers to differentiate through needle dimensions, barrel markings, plunger characteristics, safety features, and handling convenience without changing the basic syringe operating principle.

By Volume Capacity

The volume-capacity segment comprises 0.3 mL, 0.5 mL, 1.0 mL, and other formats. The 0.5 mL category held 44.22% market share in the latest capacity assessment, establishing it as the leading format. Its capacity supports commonly prescribed insulin quantities while maintaining a compact barrel that patients can handle conveniently.

Smaller-capacity syringes are useful when prescriptions require limited insulin quantities and closely spaced graduations. Their design can support users who need greater visual separation between small doses.

Larger-capacity products address higher-dose requirements and provide additional barrel volume. These products can be particularly useful where treatment protocols involve substantial insulin quantities.

Manufacturers compete by optimizing graduation readability, barrel clarity, needle attachment, plunger movement, and packaging. Offering multiple capacities allows suppliers to address diverse prescribing patterns without forcing patients to use unnecessarily large barrels. Capacity therefore remains a clinically relevant segmentation factor rather than simply a packaging difference.

By Insulin Concentration

The insulin concentration segment includes U-100, U-500, and other formulations. U-100 products accounted for 69.65% share in the latest concentration assessment, reflecting their widespread role in standard insulin administration. Dedicated markings allow prescribed units to be interpreted directly when the correct syringe and insulin concentration are paired.

U-500 syringes address concentrated insulin requirements. These products are particularly relevant for patients prescribed high quantities of insulin, where concentrated formulations can reduce injection volume. Dedicated scales can reduce the need for manual conversion.

Other concentration-specific products serve healthcare systems where different insulin standards or specialized formulations remain in use. Manufacturers operating internationally must therefore understand local prescribing patterns before establishing their product mix.

Visual differentiation is important within this segment because concentration mismatch can create dosing errors. Clear barrel printing, distinctive packaging, and explicit concentration identification are therefore integral product characteristics. Concentration-specific engineering will remain important as diabetes treatment becomes increasingly individualized.

By Diabetes Type

The diabetes-type segment comprises type 1 and type 2 diabetes. Type 2 diabetes accounted for 91.05% share in the latest insulin syringe assessment, reflecting its substantially larger patient population and the use of insulin among patients requiring injectable therapy. Insulin requirements within this group depend on disease progression, treatment response, and physician-directed management.

People with type 1 diabetes require insulin as a fundamental part of treatment because endogenous insulin production is severely impaired or absent. Administration technology therefore remains central throughout their treatment pathway.

People with type 2 diabetes can use a broader combination of treatment options, including lifestyle intervention, oral medicines, non-insulin injectables, and insulin. Syringe demand develops when vial-based insulin becomes part of the prescribed regimen.

Manufacturers serving both groups focus on dose visibility, comfortable needles, consistent manufacturing, and suitable barrel capacities. Competitive pressure from pens and pumps also affects both categories, although device adoption varies by healthcare system and patient preference.

By End User

End users include hospitals and clinics, home-care settings, and other healthcare environments. Hospitals and clinics held 47.25% share in the latest end-user assessment, demonstrating the importance of institutional procurement within the Insulin Syringes Market. These organizations require predictable product quality, sterile packaging, reliable supply, and efficient purchasing arrangements.

Home-care demand reflects the routine nature of diabetes management. Patients who self-administer vial insulin require syringes that provide clear markings, manageable plunger resistance, suitable needle dimensions, and convenient packaging.

Other users include specialized diabetes facilities, nursing environments, and additional care settings. Their requirements can vary according to patient volumes, clinical workflows, and procurement structures.

Manufacturers therefore need separate channel strategies for professional and household users. Institutional buyers emphasize procurement efficiency and standardization, whereas retail consumers may place greater importance on comfort and usability. Distribution coverage across both channels is consequently a major competitive consideration.

Regional Analysis

Regional performance in the Insulin Syringes Market reflects differences in diabetes prevalence, healthcare infrastructure, insulin access, reimbursement, manufacturing capacity, and adoption of competing delivery devices. North America maintains a leading position, Europe combines mature healthcare systems with extensive alternative-device adoption, Asia-Pacific provides a large treatment population, and Middle East & Africa presents significant access opportunities. Regional demand is also influenced by whether patients obtain insulin through institutional programs, retail pharmacies, insurance systems, or direct household spending.

Manufacturers adapt distribution and product portfolios to these differences. Developed healthcare systems typically emphasize safety engineering, regulatory documentation, and patient comfort. Emerging systems place greater emphasis on affordability and dependable supply. Local manufacturing is gaining strategic importance as healthcare systems evaluate supply-chain resilience. Competitive success consequently requires companies to balance global production standards with country-specific treatment practices and procurement structures.

North America

North America is the largest regional Insulin Syringes Market, accounting for 39.85% share in the latest geographic assessment. The United States dominates regional consumption through its large diagnosed diabetes population, hospital network, retail pharmacy infrastructure, medical-distribution system, and home-care sector.

Institutional demand is supported by hospitals, outpatient facilities, long-term care organizations, and diabetes clinics. These buyers evaluate sterility, device specifications, safety features, supplier reliability, and procurement continuity. Home users have different priorities, including readable markings, needle comfort, pharmacy availability, and straightforward disposal.

Supply-chain resilience has gained importance following concerns involving the quality of selected imported plastic syringes. This has encouraged domestic capacity expansion and greater attention to supplier qualification.

Canada contributes through publicly supported healthcare systems and structured chronic-disease management. Pharmacy networks provide an important route for home-use injection products. Mexico adds demand through public institutions, private healthcare providers, pharmacies, and distributors.

The regional competitive environment is technologically advanced. Insulin pens, continuous glucose monitoring, pumps, and automated delivery systems have substantial visibility, creating substitution pressure on traditional syringes. Conventional products nevertheless maintain relevance for vial insulin, selected institutional applications, and patients prioritizing familiar and economical administration.

Europe

Europe represents a mature market where conventional insulin syringes coexist with widespread use of pens, pumps, and connected diabetes technologies. The WHO European Region records at least 64 million adults with diabetes, sustaining significant requirements for medicines and administration products. National demand patterns differ because reimbursement structures and treatment practices vary between healthcare systems.

Hospitals emphasize compliance, traceability, sterility, and occupational safety when procuring disposable injection devices. Community pharmacies support patients who continue to administer insulin from vials. Long-term care settings also contribute to demand because trained personnel may manage medication administration for residents.

Environmental considerations are becoming increasingly relevant. Disposable syringes generate plastic components, packaging, and contaminated sharps, encouraging healthcare organizations to evaluate waste-management practices and material efficiency.

European medical-device suppliers operate within a highly regulated environment. Product documentation, manufacturing controls, quality systems, and post-market monitoring influence supplier competitiveness.

Alternative insulin-delivery devices remain the strongest competitive factor. Pen systems offer convenience, while pumps provide programmable administration for suitable users. Syringe suppliers consequently focus on dependable quality, concentration compatibility, needle engineering, and cost-effective distribution. The region remains strategically relevant because of its substantial diabetes burden and established clinical infrastructure.

Asia-Pacific

Asia-Pacific combines a substantial diabetes population with expanding medical-device manufacturing and increasing healthcare access. India alone has close to 100 million people with diabetes according to data cited during the introduction of a dedicated insulin syringe portfolio. China, Japan, India, South Korea, and Southeast Asian countries create diverse demand conditions across the region.

Affordability strongly influences device selection in many Asia-Pacific healthcare systems. Conventional syringes remain relevant where vial insulin offers an accessible treatment route and where advanced devices are not consistently reimbursed.

Manufacturing capability is another regional strength. India and China have significant medical-consumables production ecosystems, while Japan maintains sophisticated medical-device engineering capabilities. Local manufacturers compete with multinational suppliers across hospital procurement and retail channels.

Urban pharmacy expansion improves access to home-use products, while government diabetes programs can increase diagnosis and treatment participation. Rural distribution remains a challenge in countries where healthcare infrastructure is geographically uneven.

Advanced Asian markets increasingly adopt pens, pumps, and connected glucose-management systems. This creates a two-tier competitive environment in which sophisticated delivery technology expands alongside continued demand for economical disposable syringes. Suppliers able to combine competitive pricing with dependable quality can address substantial patient populations across the region.

Middle East & Africa

Middle East & Africa contains highly diverse healthcare markets ranging from well-developed Gulf systems to regions where basic diabetes treatment remains difficult to access. Diabetes prevalence is increasing across several countries, supporting long-term requirements for insulin, monitoring supplies, and administration devices. The region's demand is influenced heavily by healthcare funding, urbanization, pharmacy availability, and access to trained professionals.

A significant opportunity exists because treatment coverage remains incomplete in many lower-resource healthcare systems. Global evidence indicates that over half of people with diabetes were not receiving medication, with the lowest treatment coverage occurring in lower-income settings. Expanding diagnosis and medicine access can therefore increase the need for economical injection products.

Gulf markets increasingly use modern pens and diabetes technologies, while conventional syringes remain relevant in hospitals and selected home-care pathways. African markets rely on combinations of government procurement, private pharmacies, hospitals, distributors, and health programs.

Distribution reliability is a central competitive factor because products must reach patients beyond major metropolitan centers. Local manufacturing and regional warehousing can strengthen supply continuity. Suppliers offering clear markings, sterile packaging, competitive pricing, and dependable availability are positioned to address unmet diabetes-care requirements.

Competitive Landscape

The Insulin Syringes Market includes multinational medical-device manufacturers, specialized injection-product suppliers, regional producers, distributors, and diabetes-focused healthcare companies. Competition centers on manufacturing scale, needle engineering, dosing accuracy, safety mechanisms, product availability, regulatory compliance, and distribution strength. The leading volume-capacity category commands 44.22% market share, making mainstream syringe formats an important competitive battleground.

Large suppliers benefit from established hospital relationships and broad distribution systems. Specialized manufacturers compete through needle sharpness, concentration-specific markings, plunger engineering, low-dead-space configurations, and patient-comfort features.

Regional manufacturers can compete effectively where local production provides pricing or supply-chain advantages. Government procurement programs and hospital tenders can favor suppliers capable of delivering standardized products consistently at scale.

Competition increasingly extends beyond syringes themselves. Insulin pens, pen needles, pumps, patch systems, and automated delivery technologies compete for patient treatment pathways. Manufacturers with diversified diabetes-device portfolios can respond to these shifts more effectively than suppliers concentrated exclusively on conventional syringes.

Quality assurance is becoming a stronger differentiator as regulators and healthcare providers increase scrutiny of injection products. Automated inspection, vertically integrated needle production, reliable sterilization, and traceable manufacturing processes can strengthen supplier credibility. Market positioning therefore depends on balancing manufacturing efficiency with patient safety and clinical usability.

List of Top Insulin Syringes Companies

• Becton, Dickinson and Company (U.S.)

• B. Braun Melsungen AG (Germany)

• Terumo Corporation (Japan)

• Nipro Corporation (Japan)

• Cardinal Health, Inc. (U.S.)

• Medline Industries, LP (U.S.)

• Hindustan Syringes & Medical Devices Ltd. (India)

• ICU Medical, Inc. (U.S.)

• Baxter International Inc. (U.S.)

• Novo Nordisk A/S (Denmark)

• Biocon Limited (India)

• Eli Lilly and Company (U.S.)

• Abbott Laboratories (U.S.)

Leading Companies by Market Share

• Becton, Dickinson and Company: BD remains one of the most prominent injection-device manufacturers and is expanding its U.S. manufacturing network. The company stated that new production lines would increase domestic conventional syringe capacity by over 50%, strengthening its ability to serve healthcare providers requiring large-volume supply.

• Terumo Corporation: Terumo maintains an established international injection-device presence and provides dedicated insulin syringes alongside broader needle and syringe portfolios. Its insulin syringe platform uses a 3-bevel needle design, demonstrating the company's focus on penetration characteristics, injection comfort, and precision-oriented product engineering.

Investment Trends & Opportunities

Investment activity in the Insulin Syringes Market is increasingly directed toward production localization, automation, supply resilience, quality inspection, and advanced injection technologies. BD announced a US$35 million expansion of syringe-related manufacturing at its Columbus facility, demonstrating continued investment in domestic medical-device capacity. While not limited to insulin syringes, such investments strengthen the wider needle-and-syringe manufacturing ecosystem that supports injection-device availability.

Automation provides another investment opportunity. High-speed molding, assembly, printing, inspection, sterilization, and packaging can improve production consistency while supporting large-volume output. Machine-vision systems can identify component defects before finished devices enter distribution.

Emerging markets create opportunities for local production partnerships. Domestic manufacturing can shorten supply chains and improve access where imported medical consumables face logistical constraints. Pharmacy expansion also creates investment opportunities in distribution and patient-oriented packaging.

Safety-engineered syringes represent a further area for capital deployment. Healthcare institutions increasingly consider technologies designed to reduce accidental needle exposure among professionals.

Investors can also target material optimization and waste reduction. Disposable injection products face growing environmental scrutiny, creating incentives for efficient component design and reduced packaging. Companies combining manufacturing scale, strong quality systems, reliable distribution, and product innovation are positioned to benefit from changing procurement priorities.

Product Innovation & Development

Innovation in the Insulin Syringes Market focuses on injection comfort, dose visibility, needle performance, medication retention, and user safety. Terumo introduced an insulin syringe portfolio incorporating plunger-retention technology intended to reduce spillage during administration. Such engineering illustrates how manufacturers can improve conventional devices without adding electronic complexity.

Needle technology remains a major innovation area. Manufacturers refine bevel geometry, siliconization, wall thickness, and tip consistency to support smooth penetration and medication flow. Fixed-needle construction can also reduce residual medication compared with configurations that contain additional connection spaces.

Barrel design is evolving through clearer graduation printing and improved contrast. These characteristics are particularly important for patients who prepare doses independently. Concentration-specific markings provide additional differentiation by aligning syringe scales with the insulin being administered.

Low-dead-space construction is receiving increased attention because it can reduce medication retained inside the device after injection. Safety systems are also expanding through retractable or shielded needle concepts designed for professional healthcare environments.

Manufacturing technology supports product innovation through automated inspection. Camera-based systems can detect alignment problems, printing defects, component damage, and assembly inconsistencies. Product development is therefore increasingly combining mechanical refinement with sophisticated manufacturing controls to produce simple devices with higher levels of consistency and usability.

Recent Developments (2023–2026)

• In January 2026, Terumo launched the SurTract Safety Syringe in the United States using passive automatic needle retraction intended to reduce post-injection needlestick exposure.

• In January 2026, BD announced a US$110 million expansion of its Nebraska injectable-device manufacturing infrastructure to strengthen domestic syringe and cannula production capabilities.

• In August 2025, BD announced an expansion of its Columbus manufacturing facility to add syringe production lines and strengthen the resilience of its U.S. medical-device supply network.

• In January 2025, BD disclosed additional U.S. manufacturing expansion designed to increase conventional syringe production capacity and strengthen domestic availability of critical injection products.

• In November 2023, Terumo India introduced dedicated insulin syringes designed with concentration-specific markings, sharpened needle geometry, and plunger-retention features for routine insulin administration.

Scope of the Insulin Syringes Market Report

The Insulin Syringes Market report examines disposable syringe products specifically designed or routinely used for insulin administration across professional and home-care environments. The analytical scope includes capacity, insulin concentration, diabetes type, end-user demand, regional performance, competitive positioning, investment activity, product innovation, manufacturing trends, and supply-chain developments.

Capacity analysis begins with the 0.3 mL format and evaluates how barrel size influences dosing requirements, graduation visibility, patient handling, and product selection. Larger formats are assessed according to their suitability for different prescribed quantities.

Concentration coverage evaluates standard and concentrated insulin requirements, with particular attention to scale compatibility and dose interpretation. Diabetes-type analysis distinguishes the treatment characteristics associated with insulin-dependent patients and those who transition to insulin during disease management.

End-user coverage considers hospitals, clinics, home-care environments, pharmacies, long-term care facilities, and other relevant settings. Regional analysis addresses North America, Europe, Asia-Pacific, and Middle East & Africa while examining healthcare infrastructure, treatment access, reimbursement, distribution, and device preferences.

Competitive coverage evaluates manufacturers according to product portfolios, needle engineering, manufacturing capability, safety technology, quality systems, and geographic reach. The report also assesses competitive substitution from insulin pens, pumps, and connected delivery technologies. Its scope is therefore centered specifically on the clinical, manufacturing, distribution, and technological factors shaping global insulin syringe demand.